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Abstract: Chronic obstructive pulmonary disease (COPD) is the most common chronic 
respiratory condition in adults and is characterized by progressive airflow limitation that is 
not fully reversible. The main etiological agents linked with COPD are cigarette smoking and 
biomass exposure but respiratory infection is believed to play a major role in the pathogenesis of 
both stable COPD and in acute exacerbations. Acute exacerbations are associated with more rapid 
decline in lung function and impaired quality of life and are the major causes of morbidity and 
mortality in COPD. Preventing exacerbations is a major therapeutic goal but currently available 
treatments for exacerbations are not very effective. Historically, bacteria were considered the 
main infective cause of exacerbations but with the development of new diagnostic techniques, 
respiratory viruses are also frequently detected in COPD exacerbations. This article aims to 
provide a state-of-the art review of current knowledge regarding the role of infection in COPD, 
highlight the areas of ongoing debate and controversy, and outline emerging technologies and 
therapies that will influence future diagnostic and therapeutic pathways in COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic progressive disease which 
is characterized by an inexorable decline in respiratory function, exercise capacity, and 
health status. This chronic clinical course of COPD is punctuated by periods of increased 
symptoms that are termed “acute exacerbations”. Acute exacerbations are significant events 
in the course of the disease as they accelerate disease progression, impair quality of life, 
and are the major contributor to morbidity and mortality in COPD. In addition they are 
the major cause of excess health care costs as they often result in unscheduled health care 
visits, treatment costs, and hospitalizations. Therefore, preventing exacerbations is a major 
therapeutic goal that has not been achieved with currently available treatments. The major 
causes of exacerbations are respiratory infections with both viruses and bacteria. Although a 
role for infection in both stable COPD and COPD exacerbations has long been established, 
controversy remains regarding a number of issues including the effect of bacterial infection 
in stable COPD, the relative contributions of viruses and bacteria in COPD exacerbations, 
mechanisms of susceptibility to infection, and the role of antibiotics.
Microbial flora in the normal lung  
and in COPD patients
In order to investigate the role of infection in COPD, an understanding of the 
normal microbial flora in healthy individuals is required. Most of the surfaces of the 
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upper respiratory tract (including nasal and oral passages, 
nasopharynx, and oropharynx) are colonized by bacteria in 
healthy individuals. These organisms constitute the normal 
flora of the respiratory tract and rarely cause disease. The nose 
is commonly colonized with predominantly Staphylococcus 
epidermidis and Cornyebacteria but Staphylococcus aureus 
can also be present. The nasopharynx is predominantly 
colonized with non-hemolytic and alpha-hemolytic 
Streptococci and Neisseria species with occasional carriage 
of Streptococcus pneumonia and Haemophilus influenzae.1 
Determining the prevalence of bacteria in the lower 
respiratory tract has proved problematic due to the difficulty 
of obtaining lower respiratory tract samples uncontaminated 
by upper airway secretions. Bronchoscopy with protected 
brush specimens is the best method of avoiding upper airway 
contamination. A report by Rosell et al pooled the results 
of studies using bronchoscopy in healthy subjects and both 
stable and exacerbated COPD.2 In 70 healthy participants, 
potentially pathogenic microorganisms (PPMs) were cultured 
in only 6% of subjects and bacterial loads were low. Two 
subsequent studies not included in this analysis reported that 
PPMs were present in 10% of subjects undergoing diagnostic 
bronchoscopy in whom no pathology was found,3 and in 3% 
of a group of healthy smokers and ex-smokers.4 Therefore 
based on these findings, conventional wisdom has been that 
the lower respiratory tract in healthy individuals is sterile. 
However it has been estimated that over 70% of the bacterial 
species present on mucosal surfaces cannot be cultured using 
currently available standard culture techniques. Several 
recent studies have used novel molecular approaches for 
bacterial detection rather than standard culture techniques 
and have challenged the idea that the lower respiratory tract 
is predominantly sterile. These studies will be discussed in 
further detail in a later section.
In contrast to healthy individuals, bacteria can often be 
cultured from lower airway secretions in COPD patients. 
The pooled analysis by Rosell et al reported that PPMs are 
present at a concentration of 102 cfu/mL or greater in 29% 
of stable COPD patients2 and Sethi et al detected bacteria in 
34.6% of patients.4 No bacteria were present in patients with 
mild disease (GOLD criteria), but 24% of moderate patients, 
45% of severe patients, and 33% of very severe patients had 
bacteria detected. This relationship between lung function 
impairment and bacteria has been reported in some studies5 
but other studies have found no relationship.3,4,6–8 Studies 
using sputum to detect bacterial infection have generally 
found higher rates of bacterial isolation than the bronchos-
copy studies with bacteria found in up to half of stable COPD 
patients.9–11 This is likely due to higher rates of contamination 
with upper respiratory organisms in sputum.
The most common organisms cultured in COPD from 
both sputum and bronchoscopic samples are consistently 
Haemophilus influenza, Streptococcus pneumonia, and 
Moraxella catarrhalis. However the bacterial flora in COPD 
varies with disease severity as Gram negative organisms such 
as Pseudomonas aeruginosa are more commonly detected 
in patients with more severe airflow obstruction in both 
stable COPD12,13 and in exacerbations.14–16 Other organisms 
detected less frequently include Haemophilus parainfluenzae 
and Staphylococcus aureus but the significance of these 
organisms is debated (Table 1).
Respiratory microbiome
Our current understanding of the role of bacteria in the 
pathogenesis and progression of obstructive airways 
disease is predominantly based upon classical microbial 
culture techniques. However, these suffer from a number 
of limitations, are very labor intensive, and using standard 
Table 1 The Respiratory Microbiome in Health, in stable COPD and exacerbated COPD
Healthy individuals Stable COPD  
(mild to moderate)
Stable COPD  
(moderate to severe)
Exacerbated COPD
Staphylococcus epidermidis1 Haemophilus influenza12,13 Haemophilus influenza12,13,19 Moraxella catarrhalis69
Cornyebacteria1 Streptococcus pneumonia12,13 Streptococcus pneumonia12,13 Streptococcus pneumonia69
Staphylococcus aureus1 Moraxella catarrhalis12,13 Moraxella catarrhalis12,13 Haemophilus influenza70
Non-hemolytic streptococci1 Haemophilus parainfluenzae73 Pseudomonas aeruginosa12,13,23 Pseudomonas aeruginosa14,16
Alpha-hemolytic streptococci1,19 Staphylococcus aureus70 Haemophilus parainfluenzae73 Staphylococcus aureus70,71
Neisseria spp.1 Staphylococcus aureus70 Haemophilus parainfluenzae73
Streptococcus pneumonia (occasional)1,19
Haemophilus influenza (occasional)1,19
Prevotella spp.19
Fusobacteria19
Veillonella19
Abbreviation: COPD, cheronic obstructive pulmonary disease.
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conditions can culture only 30% of bacteria.17 It is 
therefore understandable that historically the lungs have 
been considered sterile, despite their continuity with the 
upper airways, proximity to the gastrointestinal tract, and 
continuous exposure to the environment. Over the past 
decade molecular culture independent techniques, initially 
developed in the ecology field, have identified bacteria 
previously not amenable to culture.18 These techniques when 
combined with advances in sequencing technologies have 
produced a powerful tool for investigating the role of bacteria 
in health and disease and have recently begun to shed more 
light on the role of bacteria in COPD.
Molecular tools rely on genomic evolutionary relationships 
between bacteria and use similarities in housekeeping genes, 
such as the highly conserved 16S rRNA gene, to assign 
phylogeny. These techniques can not only be used to rapidly 
identify individual bacterial species but also to build up a picture 
of the complete microbial community in an environment (the 
microbiome), offering a more comprehensive analysis than 
classical culture-based techniques.
Hilty et al employed these techniques to clearly 
demonstrate the presence of a wide variety of bacteria in the 
airways of healthy non-smoking subjects, establishing the 
existence of a respiratory microbiome and challenging 
the dogma of lung sterility.19 Their study also suggested the 
healthy respiratory microbiome differs from that associated 
with a number of respiratory diseases including COPD.
COPD is linked inherently to smoking and we must 
therefore first look at the effects of smoking on the respiratory 
microbiome. Interestingly, three studies have now found no 
overall difference in total bacterial levels between lower 
airways samples from smokers, non-smokers, and COPD 
subjects.19–21 However Charlson et al have demonstrated 
changes in bacterial communities in the upper respiratory 
tract of smokers, with significant loss of bacterial diversity 
when compared to the oro- and naso-pharynx of non-
smokers.22 Whether this represents outgrowth of an organism 
from a healthy community leading to loss of diversity remains 
unclear, but loss of microbial diversity has been associated 
with an increased incidence of disease in other systems.23
Although the number of studies examining the lower 
airways microbiome in COPD is limited, it is already clear 
that there is a significant overlap between the bacteria seen 
in COPD and healthy individuals.19,20,24 This has led some 
authors to postulate the existence of a core respiratory 
microbiome made up of Pseudomonas, Streptococcus, 
Prevotella, Fusobacteria, Haemophilus, and Veillonella 
species whose relative abundance differs between health 
and disease.25 Certainly, in the initial study by Hilty et al, 
Haemophilus species were most strongly associated with the 
presence of COPD,19 while the dominance of Pseudomonas 
species and associated lower diversity of the microbiome was 
observed in subjects with moderate or severe COPD but not 
in mild disease.20 However, a recent study by Sze et al did not 
observe any reduction in microbial diversity in lung tissue 
from patients with very severe COPD (GOLD stage IV). 
Although they do report evidence of a unique bacterial 
community structure in this group with a significantly greater 
abundance of Firmicutes compared to smoking and non-
smoking controls.21
Using explanted lungs, Erb-Downward and colleagues 
were able to characterize the microbial communities at 
different locations without the need for bronchoscopy, 
thereby avoiding any potential upper airways contamination. 
They demonstrated bacterial communities similar to those 
seen in bronchoalveolar lavage (BAL), and interestingly 
demonstrated significant micro-anatomical differences in 
community composition within the lungs. Highlighting the 
power of technology, the segmental bronchus of the left upper 
lobe bronchus in one subject was dominated by Haemophilus, 
while in the distal bronchus of the left upper lobe bronchus, 
Stentrophomonas dominated the community.20
Molecular microbiology has currently raised more questions 
than it has answered in the respiratory field. These techniques 
have clearly demonstrated the presence of PPMs in the lungs 
of healthy smokers and COPD subjects and have begun to 
identify differences between the bacterial communities in 
these groups and between severe and mild disease. However, 
it remains unclear what impact this could have on our 
understanding of the disease pathogenesis and progression. 
How does the microbiome change before, during, and after 
an exacerbation? What effect do viral infections have on the 
bacterial communities? Further studies are clearly needed to 
answer these questions but with these tools and the evolving 
field of metatranscriptomics, we have the opportunity to 
study the role of bacteria in obstructive lung disease more 
comprehensively than ever before.
Significance of bacterial infection  
in stable COPD
The presence of bacteria in the lower respiratory tract in 
stable COPD patients is usually termed “colonization” rather 
than “infection”, implying that the bacteria present have no 
or minimal pathological significance. However, studies have 
now established that there may be relationships between the 
presence of bacteria and both airways inflammation and 
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adverse clinical outcomes in COPD patients. Therefore the 
term “colonization” may be misleading and the presence of 
bacteria in COPD patients may not be as benign as  previously 
thought.
Increased levels of cellular and soluble inflammatory 
markers in the airways including neutrophils, CXCL8, 
leukotriene B
4
 (LTB
4
), myeloperoxidase (MPO), matrix 
metalloproteinase (MMP), tumor necrosis factor-α (TNF-α), 
IL-1β, IL-6, IL-12, and neutrophil elastase (NE) have 
been reported in stable COPD patients with bacterial 
infection.4,6,8,11,26–29 In addition two studies have reported a 
quantitative relationship between bacterial load and sputum 
inflammatory markers.6,9 Bacterial infection is also associated 
with adverse clinical outcomes with an increased frequency 
of exacerbations,9,11,30 impaired health status,26,29 and systemic 
inflammation.26,29 One study did not find an association 
between bacterial infection and exacerbation frequency.30 
Therefore these studies would appear to provide evidence 
that bacterial infection, even in patients who are clinically 
stable, causes airways and systemic inflammation, increases 
exacerbations, and impairs health status. However, as these 
studies were cross-sectional they could not determine the 
direction of the association between bacterial colonization 
and the outcomes measured. Bacterial infection may cause 
increased airways inflammation but reverse causation 
may be equally plausible, ie, patients with greater airways 
inflammation may be more susceptible to developing 
bacterial infection. Parameswaran et al attempted to resolve 
this issue this by studying the effect of the acquisition of a 
new strain of Moraxella catarrhalis on sputum inflammatory 
markers.31 Sputum samples collected after acquisition of 
Moraxella catarrhalis had higher levels of TNF-α, CXCL-8, 
and NE compared to pre-acquisition samples, supporting 
the hypothesis that bacteria induce airways inflammation. 
However, inflammatory markers in subjects who did and did 
not develop infection were not compared prior to acquisition 
so the hypothesis that airways inflammation predisposes to 
bacterial infection is still possible.
This study also highlighted the fact that bacterial 
colonization/infection is not a static phenomenon. This was 
further demonstrated by Wilkinson et al who studied 30 stable 
COPD patients over 1 year and collected sputum at the start 
and end of this time period.10 Fifty three percent of subjects 
had bacteria present in sputum at the start of the study. After 
1 year half of these had the same bacterial species but in the 
other 50% of subjects a different bacterial species was present. 
There was a significant increase in the mean bacterial load 
over the year and this correlated with a reduction in the forced 
expiratory volume in 1 second (FEV
1
), as did acquisition of a 
new bacterial species. A study of 40 COPD patients over an 
8-month period used molecular typing to identify the strain of 
sputum organisms. Fifty-three percent of patients had PPMs 
in sputum at both time points but only 15% had the same 
organism, whereas 38% had acquired a new organism.27
Therefore, both the presence and type of bacteria in 
the airways in stable COPD are not static phenomena and 
may be affected by factors such as disease progression, 
exacerbations, and treatments including antibiotics and 
inhaled corticosteroids. Conversely the presence of bacteria 
can influence disease progression and exacerbations in COPD 
patients. The relationships between clinical outcomes and 
bacteria in COPD are undoubtedly complex and further 
studies to investigate these should be long-term longitudinal 
studies using strain typing in addition to culture. If a 
causal relationship between the presence of bacteria and 
adverse outcomes in stable COPD patients is conclusively 
demonstrated, then intervention studies with antibiotics in 
stable COPD may be warranted.
Mechanisms of susceptibility  
to bacterial infection in COPD
In healthy individuals, bacteria are constantly inhaled but 
infection does not develop as a result of sophisticated 
host defenses. These include mechanical factors such as 
tight epithelial lining cells and mucociliary clearance, 
antimicrobial peptides (including pentraxin-3, lysozyme, 
lactoferrin, defensins, elafin, secretory leukoprotease 
inhibitors [SLPI], and cathelicidin), local immune responses 
such as secretory IgA, resident phagocytes such as airway 
macrophages, and acquired immune responses.32 The 
presence of bacterial infection in the lower airways suggests 
that host pulmonary defenses are impaired and a number 
of abnormalities in pulmonary immune mechanisms have 
been reported in COPD. Cigarette smoking has a number 
of effects on the mechanical barriers in the lung that may 
favor the development of infection. Smoking reduces ciliary 
beat frequency, induces squamous metaplasia resulting in 
reduced numbers of ciliated cells, and increases goblet cells 
and submucosal mucous glands.33 This is likely to result in 
excess production and impaired clearance of mucous from the 
airways, which favors bacterial growth. Impaired mucociliary 
clearance34 and ciliary abnormalities have been reported in 
smokers and COPD35 and therefore these may be factors 
contributing to bacterial infection in COPD. There is also 
evidence that cigarette smoke damages the epithelial 
junctions leading to increased epithelial permeability.36
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Another mechanism that has been extensively investigated 
is impaired function of airway immune cells such as 
neutrophils and alveolar macrophages in COPD. These cells 
play a key role in removing microorganisms present in the 
airways by phagocytosis and initiating immune responses. 
Absolute numbers of macrophages and neutrophils in 
the airways are actually increased in smokers and COPD 
patients, and therefore, research has focused on whether 
macrophage function in COPD is impaired. A number 
of studies have reported that macrophage phagocytosis of 
microorganisms is impaired in COPD37–42 and a number of 
mechanisms of impaired function of macrophages in COPD 
have been investigated. Reduced levels of the toll-like 
receptor TLR2 have been reported in macrophages43 and 
neutrophils44 from COPD patients. MARCO (macrophage 
receptor with collagenous structure) is a class A scavenger 
receptor expressed on macrophages that mediates binding 
and uptake of Gram-positive and Gram-negative bacteria.45 
Cigarette smoking reduces the expression of MARCO on 
macrophages resulting in impaired responses to infection 
in vitro46 and in vivo in mice.47 Interest in macrophage 
function has increased recently with studies that have 
shown that macrophage function can be restored with 
pharmaceutical agents,42,47–49 raising the possibility that 
improving the phagocytic capacity of macrophages is a 
potential therapeutic option in COPD.
Antimicrobial peptides (AMPs) are soluble molecules 
present in the airway surface fluid that constitute an important 
first line of defense against both bacterial and viral pathogens. 
AMPS include surfactant proteins (SP), defensins, elafin, 
cathelicidin, SLPI, and lysozyme. Studies of AMPs in 
COPD have had varying results with both increased50 and 
decreased51,52 human β-defensin, increased α-defensin,53 and 
increased SLPI and elafin52 reported. Therefore, it remains 
unclear whether reduced levels of AMPs contribute to 
impaired immune responses in COPD.
α1-Antitrypsin (AAT) is a member of the serine protease 
inhibitor (SERPIN) supergene family and AAT deficiency 
is associated with the development of early-onset COPD. 
The key function of AAT is the inhibition of proteases such 
as neutrophil elastase, and excess protease activity is con-
sidered the key mechanism underlying the development of 
COPD in AAT deficiency. New evidence has emerged that, 
in addition to anti-protease activity, AAT possesses anti-
inflammatory, immunomodulatory, and both antibacterial54 
and antiviral properties.55 Therefore, it is possible that AAT 
deficiency contributes to susceptibility to infection in COPD. 
AAT deficient patients experience frequent exacerbations56 
but there is no evidence that infections are more frequent 
than non-AAT deficient patients. AAT augmentation reduces 
exacerbations and this will be discussed further in the “Novel 
therapies” section.
Animal models of bacterial  
infection in COPD
Since there are no existing human models of experimental 
bacterial infection in COPD, there has been considerable 
interest in the use of animal models to investigate the 
role of bacterial infection in COPD. Animal models use 
three main approaches to establishing a COPD phenotype: 
inhalation of noxious stimuli (most commonly cigarette 
smoke exposure), instillation of tissue-degrading proteinases 
such as elastase, and genetic manipulation.57,58 Gaschler 
et al administered cigarette smoke to mice for 8 weeks and 
subsequently challenged intranasally with nontypeable 
H. influenzae (NTHI). This led to increased pulmonary 
inflammation, upregulation of inflammatory mediator 
expression but decreased bacterial burden compared to 
control mice.59 Drannik et al similarly showed that cigarette 
smoke altered the response to infection with Pseudomonas 
aeruginosa with a worsening of clinical score, increased 
inflammation, and increased expression of pro-inflammatory 
cytokines.60 Although cigarette smoke-induced models 
have the advantage of using the primary disease-causing 
agent, even with prolonged exposure, only mild pulmonary 
abnormalities are seen in mice, equivalent to human GOLD 
stage 1 or 2 disease.58,61 Therefore, studies using such models 
may be of less relevance to the study of bacterial infection 
which occurs more frequently in patients with more severe 
disease. Instillation of proteinases such as porcine pancreatic 
elastase produces more severe emphysematous changes 
which mimic those seen in advanced disease and therefore 
other studies have chosen to use these techniques to model 
bacterial COPD exacerbations.
Pang et al used a mouse model of elastase-induced 
emphysema to show that pulmonary clearance of NTHI was 
impaired.62 They also showed that intercellular adhesion 
molecule 1 (ICAM-1) was downregulated in the airway 
epithelium of elastase-treated mice and suggested that this 
may provide an underlying mechanism for the impaired 
bacterial clearance observed. However, notably, they did 
not show any differences in localized lung inflammation 
between the two groups and therefore, whether delayed 
bacterial clearance leads to clinically relevant exacerbation 
of disease in this model is unclear. Ganesan et al used a more 
complex model system of combined lipopolysaccharide 
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and elastase administration to mimic airway inflammation 
and emphysema in mice.63 When challenged with NTHI, 
elastase/LPS mice showed delayed bacterial clearance with 
an increase in neutrophilic inflammation and prolonged 
mucus secretion assessed by mucin gene expression and 
periodic acid schiff (PAS) staining on lung histology. 
Furthermore, ex vivo macrophages taken from elastase/
LPS mice showed deficient phagocytosis and this was 
demonstrated to be due to decreased expression of 
scavenger receptor A. This receptor has previously been 
shown to be important in bacterial clearance in mice64 and 
genetic mutations are also associated with increased risk 
of developing COPD in humans.65 However, the direct 
applicability of these findings to mechanisms leading to 
susceptibility to bacterial infections in patients with COPD 
requires further characterization.
Developing animal models of chronic bacterial infection 
has been difficult due to rapid clearance of bacterial agents 
by the rodent immune system, typically within 1–2 days 
of administration.57 Wang and colleagues used a hamster 
model of elastase-induced emphysema and administered 
H. influenzae encased in agar beads.66 This led to prolonged 
survival and persistence of bacteria for up to 3 weeks in 
emphysematous airways. Such models may be invaluable in 
the future to aid the study of bacterial colonization in COPD 
and its relevance to exacerbations and disease  pathogenesis. 
Furthermore, studies using molecular techniques are also 
ongoing to assess the bacterial flora in the lower  respiratory 
tract of COPD mouse models. It remains to be seen 
whether this will correlate with the emerging evidence that 
bacterial communities are disordered in human patients 
with COPD.19,20
In summary, animal models have provided some useful 
insights into the mechanisms of host defense against 
bacterial infection in COPD. However, COPD is a complex, 
multisystem disorder that is incompletely understood in 
humans and therefore, the direct relevance of animal studies 
to clinical disease remains unclear. Future studies should aim 
to further evaluate which aspects of human bacterial COPD 
exacerbations existing models accurately mimic, as well as 
translating findings from existing animal work into clinical 
disease studies.
Bacteria and COPD exacerbations
Perhaps equally controversial to the role of bacteria in the 
pathogenesis of stable COPD is the contribution of bacteria 
to COPD exacerbations.67 Bacteria are often detected in 
COPD exacerbations but the high isolation rates of bacteria 
in stable COPD means the presence of bacteria does not prove 
a  causative role. As bacteria are often present in patients who 
are clinically stable, studies have attempted to determine 
whether bacterial infection does in fact induce exacerbations 
and the potential mechanisms underlying this.
New acquisition of bacteria
Detection rates of bacterial infection in samples collected 
during exacerbations are high, but as bacteria are often 
present in stable COPD, this does not prove that the organism 
is newly acquired and caused the exacerbation. There are 
surprisingly few studies directly comparing infection rates 
in stable and exacerbated patients. Two studies from the East 
London COPD cohort reported infection rates of 48.2% and 
43% in sputum in stable patients compared to 69.6% and 
76% in exacerbated patients68,69 (P = 0.009 for the study by 
Hurst et al,69 P-value not provided for the study by Wilkinson 
et al68). The pooled analysis by Rosell et al detected 
bacterial infection in 29% of protected brush specimens 
from stable COPD patients and 54% of exacerbated patients 
(P , 0.001).2 However, Papi et al reported a non-significant 
higher incidence of bacterial detection in exacerbated patients 
(54.7% vs 37.5% when stable, P = 0.08)70 and Bafadhel et al 
detected bacterial infection in 28% of stable patients and 35% 
of exacerbations (P-value not provided).71 Therefore, not all 
studies have conclusively demonstrated that infection rates 
are higher in exacerbated patients.
Sethi et al analyzed changes in bacteria in 81 patients 
over a 56-month period using both culture and molecular 
typing methods.72 Isolation of a bacterial pathogen by 
culture was associated with a significant increase in the 
incidence of exacerbations. An exacerbation was present 
in 23.6% of visits at which pathogens were isolated from 
sputum compared with 18% of visits at which no patho-
gens were isolated from sputum (P , 0.001). An analysis 
of individual bacterial species showed that isolation of 
M. catarrhalis and S. pneumoniae was associated with 
a significant increase in the frequency of exacerbations 
whereas H. influenzae, P. aeruginosa, and Gram-negative 
bacilli were not. However, as can be seen from these data, 
the majority of visits at which a pathogen was detected were 
not associated with an exacerbation. Therefore, acquisition 
of bacterial infection in a COPD patient does not automati-
cally result in an exacerbation and it is likely that there are 
both host and pathogen factors that determine the outcome 
of bacterial infection. Further studies are needed to identify 
the key factors that determine the outcome of bacterial 
infection in COPD.
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Increased bacterial load
If acquisition of a new organism does not occur in all 
exacerbations, another possible mechanism of exacerbation 
is an increase in the load of a pre-existing organism present 
in stable COPD patients. Two studies from the East 
London cohort reported a significant increase in bacteria 
load at exacerbation compared to the stable state.68,69 
Conversely, Sethi et al reported no significant difference 
between concentrations in sputum during stable disease 
and exacerbation for H. influenzae, H. haemolyticus, and 
M. catarrhalis and actually found an inverse relationship 
between exacerbation occurrence and bacterial concentrations 
in sputum for S. pneumoniae and H. parainfluenzae.73 When 
paired comparisons of concentrations of the same strain of 
pathogens isolated from the same patient during exacerbations 
and stable visits was performed, only H. influenzae was 
present at a higher concentration in exacerbation samples. 
Therefore, whether increase in bacterial load is a major 
mechanism of exacerbation in COPD remains unclear.
New bacterial strain
Detection of bacteria by culture does not distinguish between 
different strains of the same organism. Acquisition of a 
new strain of a bacterium has been investigated as another 
mechanism of exacerbation. In the study by Sethi et al described 
previously, isolation of a new bacterial strain was associated 
with a significant increase in the frequency of exacerbation. 
Thirty-three percent of visits at which new strains were isolated 
were associated with exacerbations, compared with 15.4% of 
visits at which no new strains were isolated (P , 0.001).72 
The relative risk of an exacerbation in association with the 
isolation of a new strain of H. influenzae was 1.69 (P , 0.001), 
whereas there was no association between the isolation of 
H. influenzae by culture and an exacerbation. The relative risk 
of an exacerbation in association with the isolation of a new 
strain was 2.96 for M. catarrhalis and 1.77 for S. pneumoniae 
so strain analysis strengthened the association seen with 
culture alone. New strains of P. aeruginosa were not 
associated with exacerbations. Further evaluation of this study 
reported that bacteria identified as variant H. influenzae were 
subsequently characterized as Haemophilus haemolyticus.74 
Re-assessment of the results accounting for the previously 
misinterpreted H. haemolyticus showed that new strain 
acquisition of H. influenzae was associated with a four-fold 
increase in the incidence of COPD exacerbation. Additional 
follow-up of these patients subsequently also reported a 
significant association between acquisition of P. aeruginosa 
and exacerbation contrary to what was previously reported13 
and a study of M. catarrhalis determined that acquisition 
of a new strain is associated with 10% of exacerbations.75 
In another publication from this group, the clinical and 
inflammatory responses associated with acquisition of a new 
strain of H. influenzae, S. pneumoniae, M. catarrhalis, and 
P. aeruginosa were compared with exacerbations in which a 
pre-existing strain of one of these four species was present, 
exacerbations in which S. aureus or Gram-negative bacilli 
other than P. aeruginosa were isolated and pathogen-negative 
exacerbations.76 Of the 150 exacerbations, 26% were new 
strain, 10% were pre-existing strain, 20% were other pathogen, 
and 44% were pathogen-negative exacerbations. New strain 
exacerbations had the largest increase in airway inflammation 
with signif icantly greater changes in TNF-α and NE 
when compared with pathogen-negative and other pathogen 
exacerbations and serum CRP levels were significantly 
higher with new strain exacerbations in comparison to each 
of the other three groups. New strain exacerbations were also 
associated with greater clinical symptom scores.
Chin et al studied the pro-inflammatory effects of dif-
ferent strains of H. influenzae and demonstrated that strains 
isolated during exacerbations caused more airway neutrophil 
recruitment in a mouse model of bacterial infection and more 
inflammatory pathway activation in primary human airway 
epithelial cells cultures when compared with bacterial strains 
isolated from stable patients.77 Therefore, these data suggest 
that acquisition of a new bacterial strain is likely to be an 
important mechanism linking bacterial infection and COPD 
exacerbations, and that the risk of exacerbation differs with 
different H. influenzae strains.
Thus, the role of bacteria in COPD exacerbations is 
complex and the previously held concept of a newly acquired 
bacterial infection causing an exacerbation based on  studies 
using sputum culture is likely to prove simplistic. New 
paradigms have emerged from studies using more sophis-
ticated molecular techniques such as strain typing, and as 
these become more widely available, our understanding of 
the role of bacteria is likely to evolve further.
Virus infection in COPD
Historically, bacterial infections have been considered 
the predominant infectious causative agents of COPD 
exacerbations and this is reflected in the widespread use of 
antibiotics in their treatment. Epidemiological data reporting a 
greater frequency of exacerbations in the winter months,78 and 
frequent coryzal symptoms preceding exacerbations suggest 
that exacerbations may also be associated with respiratory 
virus infections.79 Studies investigating the role of viruses 
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in COPD exacerbations carried out in the 1970s and 1980s 
detected viruses in only ∼10%–20% of exacerbations,80,81 
casting doubt on the role of virus infection. However, the 
diagnostic methods used in these studies had low sensitivity, 
especially for the detection of rhinoviruses, which are the 
most common cause of viral upper respiratory tract infections. 
Following the development of PCR-based techniques for the 
detection of respiratory viruses in clinical samples, the role of 
viruses in a number of clinical syndromes including COPD 
exacerbations has been re-evaluated. More recent studies 
using PCR have detected the presence of a virus in 47%–56% 
of exacerbations.70,82–85 In most studies, picornaviruses 
(predominantly rhinoviruses) were the most frequently 
detected viruses, followed by influenza, parainfluenza, 
respiratory syncytial virus (RSV), and adenoviruses.86 
Therefore, these reports suggest that up to half of COPD 
exacerbations are associated with respiratory virus infection. 
However, the role of virus infection in COPD exacerbations 
continues to be debated for a number of reasons and some 
authorities have questioned whether virus infections can 
cause exacerbations in their own right or whether they simply 
predispose to secondary bacterial infection. PCR-based 
diagnostic techniques are able to detect very small amounts 
of viral RNA or DNA and therefore do not definitively prove 
the presence of live virus or prove a causative relationship. 
As is the case with bacteria, viruses can be detected in stable 
COPD but this has been studied to a much lesser extent 
and detection rates have varied from 0%83,87 to 19%.82 Few 
studies have investigated both viral and bacterial infection in 
the same exacerbations and detection rates have varied from 
6%–25%.70,85 However, it is also possible that the role of viral 
infections in COPD exacerbations has been underestimated, 
as patients are evaluated at the time of presentation which 
often occurs considerably later than the onset of exacerbation 
and viruses may no longer be detectable by this time point. 
As rapid diagnostic methods and antiviral agents become 
available, the relationship between virus infections and 
COPD will no longer be of just academic interest but will 
have potential therapeutic implications and therefore warrants 
further study.
Experimental rhinovirus infection  
in COPD
A novel tool for investigating relationships between virus 
infection and COPD exacerbations is experimental rhinovirus 
infection. Experimental infection studies have been 
previously conducted in asthmatics and yielded important 
insights into the mechanisms linking virus infection to 
exacerbations in asthma.88,89 Our group has recently reported 
the first experimental rhinovirus infection study in COPD 
patients.90 COPD patients and non-obstructed control 
subjects were infected with rhinovirus followed by sequential 
measurement of symptoms, lung function, inflammatory 
markers, and virus load. Rhinovirus infection induced 
symptomatic colds that were followed by the typical features 
of a COPD exacerbation, ie, lower respiratory symptoms, 
increased airflow limitation, and airways inflammation. 
Virus was detected in airway samples following inoculation 
but prior to the onset of symptoms and viral clearance was 
followed by symptom resolution and return of inflammatory 
markers to baseline levels. Virus load correlated strongly 
with inflammatory markers and the rhinovirus was grown 
from airway samples, confirming the presence of live virus. 
Therefore, this study is the first to directly link respiratory 
virus infection to symptoms, airflow obstruction, and airways 
inflammation in COPD patients so providing novel evidence 
that rhinovirus infection causes COPD exacerbations.
Virus infection and stable COPD
The majority of studies that have investigated virus infection 
in both exacerbated and stable patients have detected viruses 
at a greater frequency during acute exacerbations compared 
to stable state. However, there is some evidence that RSV 
is detected more frequently in stable patients with one study 
reporting a frequency of around 25% in the stable state.79 
A further study found RSV in 30% of sputum samples from 
stable patients, with detection being related to greater airway 
inflammation and to a faster decline in lung function.91 
However, other studies have not reported high rates of RSV 
infection in stable COPD patients.70,82,92 A study comparing 
virus loads between infants with acute respiratory infections 
and adult COPD patients found that virus loads were 
2000-fold higher in the infants, suggesting low-grade virus 
infection in COPD.93 The disparity between these findings 
is likely to be due to a combination of factors including 
differing sensitivity of PCR techniques used, differences 
in severity of COPD patients included, or differences in 
populations studied.94 Latent infection by adenovirus has also 
been proposed to be involved in the pathogenesis of COPD. 
Lung tissue from COPD patients has been demonstrated 
to carry more group C adenoviral DNA than matched 
non-obstructed smokers.95 Latent adenoviral infection in 
combination with cigarette smoke exposure in a guinea pig 
model caused an increase in lung volumes, airspace volume, 
and reduced surface to volume ratio compared to smoke 
exposure alone.96 Additionally, adenovirus detection has 
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been shown to be similar in exacerbated and stable COPD 
patients.97 Some authors have postulated that the presence 
of RSV and adenovirus in stable COPD may contribute to 
the pathogenesis of the disease as there are some common 
pathologic features between respiratory viral infection and 
COPD including a predominance of CD8+ T lymphocytes. 
However, this remains a largely unproven hypothesis.
Relationships between exacerbation 
etiology and clinical and 
inflammatory parameters in COPD
COPD exacerbations are associated with systemic and 
pulmonary inflammation and increased levels of inflammatory 
mediators and cells have been measured in airway samples 
including tumor necrosis factor-alpha (TNF-α),98 IL-8,98,99 
IL-6,100 leukotriene B4,101 and neutrophils,70,99,102,103 
lymphocytes,99,103 and eosinophils.70,99,103 Few studies 
have examined the relationships between the clinical and 
inflammatory parameters and specific pathogens. It has been 
reported that virus-positive exacerbations are associated with 
more symptoms, greater falls in lung function,79,104,105 higher 
sputum levels of IL-6,104,105 and IP-10,106 however, these 
studies did not perform bacterial culture. Conversely, others 
have reported that only exacerbations associated with purulent 
sputum (presumed bacterial) are associated with airways 
inflammation and greater falls in lung function68,101,107,108 and that 
bacterial load correlates with levels of inflammatory markers,108 
but did not perform virological analysis. Studies that directly 
compared clinical and inflammatory parameters in bacteria 
and virus-associated exacerbations have had contrasting 
results. Two studies reported that the presence of bacteria 
but not viruses was associated with airways inflammatory 
markers such as neutrophils, IL-8, and TNF-α.69,109 Papi et al 
found no differences in clinical outcomes between bacteria- 
and virus-associated exacerbations. Both were associated 
with increased neutrophils and neutrophil elastase but only 
virus-associated exacerbations had significantly increased 
sputum eosinophils.70 However, Bafadhel et al reported 
bacterial exacerbations were associated with increased sputum 
total cell count, neutrophils and eosinophils, and CXCL-8, 
TNF-α, IL-1β, CCL5, CCL17, CXCL11, CCL3, and CCL13, 
whereas virus-associated exacerbations had greater falls in 
lung function and increased CCL5, CXCL10, and CXCL11.71 
Sethi et al compared the inflammatory responses to different 
bacteria species in COPD exacerbations and reported that 
H. influenzae and M. catarrhalis were associated with 
inflammatory markers in sputum whereas the inflammatory 
profile of H. parainfluenzae-associated exacerbations was no 
different from pathogen-negative exacerbations.108 Therefore, 
no clear pattern of clinical features or inflammatory markers 
has emerged that is specific to either bacterial or viral infection 
in COPD exacerbations. It is possible that the inflammatory 
pathways activated are the same irrespective of exacerbation 
etiology; however, studies are needed with intensive sampling 
and advanced diagnostic methods for both bacteria and viruses 
to investigate this further.
Susceptibility to virus infection  
in COPD
Cigarette smoking increases susceptibility to infection 
with respiratory viruses, but it is not established whether 
COPD is associated with increased risk of virus infection. 
In vitro studies have shown that cigarette smoke impairs 
the release of IFN-β and IFN-α.110 BAL cells from COPD 
patients infected ex vivo with rhinovirus, demonstrated 
deficient induction of IFN-β with similar trends for deficient 
induction of IFNs-α and -λ, associated with deficiency of 
the interferon-stimulated gene CXCL10.90 Similar findings 
have been reported in a mouse model where persistence of 
rhinovirus, increased airways inflammation, and deficient 
induction of IFNs-α, β, and -γ were reported in COPD mice 
compared to controls.111 However, in vitro rhinovirus infection 
of epithelial cells from COPD patients resulted in higher 
virus load and increased inflammatory mediators, but no 
differences in interferon production compared to cells from 
control subjects.112 Rhinoviruses bind to cells via intercellular 
adhesion molecule-1 (ICAM-1, major group rhinoviruses) or 
members of the low-density lipoprotein receptor family (minor 
group rhinoviruses). ICAM-1 is upregulated on the bronchial 
epithelium of patients with COPD,112,113 and therefore, it is 
possible that increased ICAM-1 levels may permit greater virus 
binding and increased viral entry into epithelial cells in COPD 
patients. Further studies investigating mechanisms of virus 
infection in COPD are required and this may lead to potential 
future therapies for virus-induced exacerbations.
Treatment of infection in COPD 
exacerbations
The controversy surrounding the role of bacteria in COPD is 
mirrored in the debate regarding the efficacy of antibiotics in 
COPD exacerbations. The current GOLD guidelines acknowledge 
this ongoing controversy and the poor quality of the clinical trials 
on antibiotics. This is reflected in the fact that there is no Grade A 
evidence on which the guidelines based their recommendations.114 
However, antibiotic use in COPD exacerbations is widespread 
with >80% of patients in secondary care and 50% of patients 
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managed in primary care treated with antibiotics.117,118 Therefore, 
antibiotic use in COPD may be excessive and contribute to 
antimicrobial resistance.
Antibiotics in COPD exacerbations
In the GOLD guidelines, the evidence for antibiotic use 
in COPD exacerbations is classed as Category B which is 
defined as “few randomized trials exist, they are small in size, 
they were undertaken in a population that differs from the 
target population of the recommendation, or the results are 
somewhat inconsistent.” There are numerous studies of anti-
biotics in COPD exacerbations but the majority of these are 
head-to-head comparisons of different antibiotics and there are 
few placebo-controlled trials. The placebo-controlled trials 
that are available are affected by a number of methodological 
issues including small numbers of patients, different outcome 
measures assessed at different time points, inclusion of patients 
without COPD, varying severities of exacerbation, and dif-
ferent antibiotics. A Cochrane review in 2006 identified 11 
placebo-controlled trials of antibiotics in COPD including a 
total of 917 patients. Antibiotic use was associated with sig-
nificant reductions in mortality, treatment failure, and sputum 
purulence, but no improvement in arterial blood gas parameters 
or peak expiratory flow.119 However, there was considerable 
heterogeneity across the trials and a number of issues that cast 
doubt on how applicable these findings are to modern man-
agement of COPD exacerbations. The review included trials 
carried out over a wide time period (1965–2001) with only four 
studies post-1990 and as the definition of COPD has changed 
markedly, no uniform COPD classifications such as the GOLD 
stages could be determined from the studies. Studies included a 
mixture of exacerbation severities ranging from patients treated 
in the community to patients requiring mechanical ventilation, 
corticosteroid use was poorly documented, a range of different 
antibiotics was used, and outcome measures such as quality of 
life measures not recorded. Therefore, it is debatable whether 
it is valid to extrapolate these findings to modern day practice. 
A more recent study included hospitalized COPD patients, all 
of which were treated with oral corticosteroids and randomized 
to receive doxycycline or placebo.120 The primary end point 
was clinical response on day 30 and the study found no differ-
ence between groups in this outcome measure. Doxycycline 
was shown to be superior to placebo in a number of secondary 
outcomes. On day 10, clinical success was achieved in 80% 
of patients in the doxycycline group and 69% in the placebo 
group (OR: 1.9; 95% CI: 1.1–3.2; P = 0.03) in the intention-
to-treat analysis but this significant difference was lost in the 
per-protocol population. Open-label antibiotic treatment for 
lack of efficacy, day 10 symptom scores, and positive bacte-
riological cultures were higher in the placebo group. However, 
treatment failure and changes in lung function were not sig-
nificantly different between groups.
Therefore, despite the widespread use of antibiotics in 
COPD exacerbations, the evidence for a beneficial effect is 
not compelling. Studies have attempted to identify factors 
that can identify patients who will benefit significantly from 
antibiotics therapy. Anthonisen et al studied 173 COPD 
patients with 362 exacerbations for 3.5 years and treated with 
antibiotics or placebo in a randomized, double-blind, crossover 
fashion.121 Exacerbations were classified into three groups: 
type 1 exacerbations comprised worsening dyspnea, increased 
sputum volume, and purulence, type 2 exacerbations were 
any two of these symptoms, and type 3 was any one of these 
symptoms with evidence of fever or an upper respiratory tract 
infection. Outcome was defined as success, no resolution, or 
deterioration, all assessed at 21 days. Patients with a type I 
exacerbation receiving antibiotics had a higher success rate 
compared to placebo (62.9% vs 43%, P = 0.01) but no benefit 
was seen for patients with type II (70% vs 60%) and type 
III (74% vs 70%) exacerbations. However in the study by 
Daniels et al the treatment effect did not differ significantly 
between the Anthonisen groups.120 A meta-analysis of ten trials 
including 1557 patients by Puhan et al reported that the effects 
of treatment varied according to the severity of exacerbations. 
Antibiotics did not significantly reduce treatment failure in 
mild to moderate exacerbations treated as outpatients but did 
so in severe exacerbations requiring hospital admission.122 
These findings were confirmed by Quon et al and together 
these studies indicate that the beneficial effect of antibiotics 
may be restricted to more severe exacerbations.123 Sputum 
purulence has also been proposed as a marker of bacterial 
infection124–128 and there is evidence that withholding antibi-
otics from patients without purulent sputum is safe,124,129 but 
these studies were not randomized.
The use of procalcitonin (PCT) as a marker of bacterial 
infection has been studied in a number of clinical syndromes 
including COPD exacerbations. Procalcitonin levels in the 
serum are low in the healthy state and become elevated in 
response to bacterial infections, but this response is attenuated 
by cytokines released in response to viral infection. Christ-Crain 
et al evaluated the use of procalcitonin to guide antibiotic 
therapy in respiratory tract infections including patients with 
COPD exacerbations.130 Patients were assigned to either 
a standard therapy arm where antibiotics were prescribed 
according to clinical judgment, or a procalcitonin-guided arm 
in which antibiotics were given only to patients with raised 
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PCT levels. Eighty-seven percent of the COPD patients in 
the standard therapy group received antibiotics compared to 
38% in the procalcitonin group (P = 0.0001) and there were 
no differences in outcomes between the groups. This group 
then carried out a similar study in COPD exacerbations only 
and reported that antibiotic prescribing was reduced by 32% 
in the procalcitonin group compared to the standard therapy 
group.131 There were no differences in outcomes between the 
two study arms and importantly, antibiotic prescribing was 
not different up to 6 months after the index exacerbation. 
There was no relationship between PCT levels and sputum 
purulence, Anthonisen type, or sputum cultures.
Therefore, despite the widespread use of antibiotics 
in COPD exacerbations, the evidence for this usage is 
surprisingly weak. Antibiotic use has a number of adverse 
effects both in terms of direct side effects for patients and 
effects on antimicrobial resistance. With increasing use of 
self-management plans for COPD patients132 and increasing 
numbers of elderly patients with COPD, the prescribing of 
antibiotics and the associated adverse effects are likely to 
increase with current management strategies. The validation 
of biomarkers and identification of clinical characteristics 
that identify exacerbations likely to be bacterial are urgently 
needed to guide rational antibiotic prescribing in COPD.
Antibiotics in stable COPD
Recognition of the potential role of bacteria in amplifying 
airways inflammation in stable COPD has led to interest in 
treating bacterial infection not only in exacerbations but also in 
stable patients. This approach is not new as trials of prophylactic 
antibiotics in chronic bronchitis were first carried out in the 
1960s. A meta-analysis of nine such trials showed some 
reduction in exacerbation time and a small but non-significant 
effect on exacerbation frequency.133 The lack of clear efficacy 
and concerns around the development of antibiotic resistance 
meant that this approach to antibiotic use in COPD was not 
pursued until more recently. Long-term macrolide antibiotics 
have been used in a number of chronic respiratory diseases 
including cystic fibrosis, asthma, and obliterative bronchiolitis. 
It is unclear whether the clinical benefits of macrolides are 
due to their antimicrobial effects as anti-inflammatory and 
immunomodulatory effects have also been described in vitro. 
In view of their beneficial effect in pulmonary diseases, their 
effect in COPD has been examined. Seemungal et al assessed 
the effects of erythromycin administered over 1 year in 
COPD and reported a significant reduction in exacerbations 
in the treatment group.134 No effect on airway or systemic 
inflammatory markers was seen, suggesting that exacerbations 
were reduced through an antibacterial mechanism. A trial 
of the macrolide antibiotic azithromycin 250 mg once daily 
for 1 year in patients with COPD reported a reduction in 
exacerbations and improvement in quality of life measures in 
the treatment arm.135 However, azithromycin was associated 
with a slight increase in hearing impairment and a doubling 
of macrolide resistance in respiratory pathogens isolated from 
nasopharyngeal swabs. An association between exposure 
to macrolides and macrolide resistance in pneumococci in 
COPD has also been reported,136 and therefore, caution may be 
required before embarking on long-term antibiotic treatment 
in large populations of COPD patients.
The risk of development of antibiotic resistance is 
reduced if either short courses or pulsed courses of antibiotics 
are used. A short course (5 days) of moxifloxacin in stable 
COPD patients with bacterial infection demonstrated 
eradication rates of 75% compared to 30% with placebo 
(P = 0.01). However, infection rates were similar at 8 weeks 
and there was no difference in exacerbation rates over a 
5-month follow-up period indicating that the effect of the 
antibiotic was short-lived.137 A randomized controlled trial of 
the fluoroquinolone antibiotic moxifloxacin to patients with 
COPD as a pulsed dose for 5 days every 8 weeks reported 
reduced exacerbations in the per-protocol analysis, but no 
significant effect was noted on exacerbations in the intention-
to-treat analysis.138 A subgroup analysis of the per-protocol 
group showed that patients with mucopurulent or purulent 
sputum at baseline had a 45% reduction in the occurrence of 
exacerbations. There was no evidence to suggest development 
of significant bacterial resistance during the trial.
Therefore, the role of antibiotics in stable COPD remains 
to be clearly defined and the benefits weighed against the 
potential risks of increased microbial resistance and other 
adverse effects.
Novel treatments for COPD 
exacerbations
In view of the evidence implicating respiratory viruses in 
COPD exacerbations, anti-viral agents may have potential 
as treatment in COPD exacerbations. Drugs have been 
developed that are active against rhinoviruses including the 
capsid-binding agent pleconaril.139 Despite demonstrating 
clinical benefit in reducing the severity of symptoms, 
pleconaril was not approved as a treatment for the common 
cold. Pleconaril has also been investigated as a treatment for 
asthma exacerbations but the results have not been reported 
yet.140 If antiviral agents demonstrate benefit in asthma, then 
trials in COPD may be warranted. The observation that AAT 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
565
Infection in COPD
International Journal of COPD 2012:7
has antimicrobial activity suggests administration of AAT 
as a potential novel therapeutic approach for COPD.55 In 
AAT-deficient COPD patients, AAT augmentation therapy is 
associated with reductions in exacerbations141,142 and in cystic 
fibrosis, inhaled AAT reduces Pseudomonas ssp. load.54 
However it remains to be determined whether administration 
of AAT is beneficial in non-AAT deficient COPD.
Conclusion
In conclusion, infection with both bacteria and viruses plays 
a major role in both stable COPD and acute exacerbations. It 
is clear that infection can have multiple outcomes including 
resolution, chronic infection, and exacerbation, and complex 
interactions between host and pathogen factors are likely to 
determine the outcome. Previous concepts of “colonization” in 
stable patients are no longer valid with the evidence that even 
in stable patients, the presence of bacteria is associated with 
adverse outcomes. New diagnostic methods that can detect 
different strains of the same bacterial species and reveal the 
presence of bacteria not detected by culture methods are likely 
to further advance our understanding of the role of bacteria in 
COPD. Finally, the development of anti-viral agents and the 
validation of biomarkers that can identify specific infectious 
agents will lead to the use of pathogen-directed therapy in 
exacerbations.
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